Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer

BACKGROUND: Both apatinib and programmed death 1 (PD-1) monoclonal antibody (mAb) monotherapy have been licensed in China for the third-line treatment of advanced gastric cancer (AGC). However, whether the combination could improve the prognosis of patients with AGC after second-line treatment has n...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Qingli, Mao, Yuefeng, Wu, Daoyuan, Hu, Yanhui, Ma, Dongyang, Zhang, LiHan, Liu, Huaimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650409/
https://www.ncbi.nlm.nih.gov/pubmed/36387189
http://dx.doi.org/10.3389/fonc.2022.952494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650409/
https://www.ncbi.nlm.nih.gov/pubmed/36387189
http://dx.doi.org/10.3389/fonc.2022.952494

Ejemplares similares